Nelson R P
Department of Urology, Medical University of South Carolina, Charleston 29425-2280.
South Med J. 1989 Jan;82(1):26-8. doi: 10.1097/00007611-198901000-00008.
After evaluating approximately 500 patients to identify the cause of erectile dysfunction, I selected 60 patients to receive a therapeutic injection of the vasoactive drugs papaverine and phentolamine mesylate (Regitine) into the corpora cavernosa. Fifty-two patients (87%) obtained erections that were adequate for sexual intercourse; these patients continued a self-injection program. Older patients with vasculogenic erectile dysfunction responded poorly. Ten patients, seven of whom had responded adequately, subsequently had implantation of a penile prosthesis. Although the self-injection group had few complications, 16 of 30 patients (53%) who had long-term follow-up subsequently discontinued the injections.
在评估了约500名患者以确定勃起功能障碍的病因后,我挑选了60名患者接受向海绵体内注射血管活性药物罂粟碱和甲磺酸酚妥拉明(立其丁)的治疗。52名患者(87%)勃起程度足以进行性交;这些患者继续进行自我注射治疗方案。血管源性勃起功能障碍的老年患者反应不佳。10名患者随后植入了阴茎假体,其中7名患者之前反应良好。虽然自我注射组并发症较少,但在30名接受长期随访的患者中,有16名(53%)随后停止了注射。